| 标题 |
Neoadjuvant trastuzumab deruxtecan alone or followed by paclitaxel, trastuzumab, and pertuzumab for high-risk HER2-positive early breast cancer (DESTINY-Breast11): a randomised, open-label, multicentre, phase 3 trial |
| 网址 | |
| DOI | |
| 其它 |
期刊:Annals of Oncology 作者:Nadia Harbeck; Shanu Modi; Lajos Pusztai; Shinji Ohno; Jiong Wu; et al 出版日期:2025 |
| 求助人 | |
| 下载 | 该求助完结已超 24 小时,文件已从服务器自动删除,无法下载。 |